ストックスクリーナーアプリを入手
25.99
4.71%
1.17
アフターアワーズ：
26.00
0.01
+0.04%
前日終値:
$24.82
開ける：
$24.61
24時間の取引高:
24,664
Relative Volume:
0.67
時価総額：
$183.07M
収益：
-
当期純損益:
$-4.98M
株価収益率:
-19.72
EPS:
-1.3177
ネットキャッシュフロー:
$-3.85M
1週間 パフォーマンス:
+0.23%
1か月 パフォーマンス:
-6.14%
6か月 パフォーマンス:
-29.34%
1年 パフォーマンス:
+2,103%
1日の値動き範囲:
$24.61
$26.37
1週間の範囲:
$24.00
$26.37
52週間の値動き範囲:
$0.94
$79.02
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
DRUG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
25.99 | 183.67M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-13 | 開始されました | TD Cowen | Buy |
| 2025-05-07 | 開始されました | Chardan Capital Markets | Buy |
| 2025-01-23 | 開始されました | Piper Sandler | Overweight |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Bright Minds Biosciences Inc (DRUG) 最新ニュース
Why Bright Minds Biosciences Inc. stock attracts strong analyst attentionTop Performer Shortlist - Newser
How Bright Minds Biosciences Inc. stock performs during market volatilityFree Trading Group - Newser
What makes Bright Minds Biosciences Inc. stock price move sharplyRisk Controlled Trading Ideas - Newser
Why TBCH stock attracts strong analyst attentionTop Momentum Stock Pick - Newser
How To Trade (DRUG) - news.stocktradersdaily.com
Cantor Fitzgerald Forecasts DRUG FY2025 Earnings - Defense World
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Rating of “Buy” by Analysts - Defense World
4,793 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Acquired by Bank of America Corp DE - Defense World
DRUG FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World
6,600 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Acquired by Jane Street Group LLC - Defense World
40,379 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Purchased by Millennium Management LLC - Defense World
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Buy” from Analysts - Defense World
(DRUG) Investment Analysis and Advice - news.stocktradersdaily.com
Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Bright Minds Showcases Revolutionary CNS Drug Portfolio at Major Jefferies Healthcare Conference - Stock Titan
HC Wainwright Issues Pessimistic Outlook for DRUG Earnings - Defense World
What is Chardan Capital’s Forecast for DRUG FY2025 Earnings? - Defense World
Chardan Capital Reiterates “Buy” Rating for Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Bright Minds Biosciences (DRUG) Receives Consistent 'Buy' Rating from Chardan Capital | DRUG Stock News - GuruFocus
Bright Minds (DRUG) Schedules Virtual R&D Day to Discuss Epileps - GuruFocus
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 - The Manila Times
Top Neurologists Reveal Latest Absence Epilepsy Breakthrough: Bright Minds Showcases Phase 2 Trial Progress - Stock Titan
FY2025 Earnings Forecast for DRUG Issued By Chardan Capital - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded at Cantor Fitzgerald - Defense World
Bright Minds Biosciences (DRUG) to Release Earnings on Wednesday - Defense World
TD Cowen Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy Recommendation - Nasdaq
Bright Minds stock rating initiated with Buy at TD Cowen - Investing.com Australia
TD Cowen Initiates Coverage on Bright Minds Biosciences (DRUG) w - GuruFocus
Bright Minds stock rating initiated with Buy at TD Cowen By Investing.com - Investing.com Nigeria
Bright Minds Biosciences Says BMB-101 Eliminated Drop Attacks in Mouse Model of Epilepsy - marketscreener.com
Bright Minds (DRUG) Reports Promising Results in Epilepsy Research | DRUG Stock News - GuruFocus
Bright Minds reports BMB-101 eliminates drop attacks in mice By Investing.com - Investing.com Nigeria
Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 - The Manila Times
Bright Minds (DRUG) Gains 'Buy' Rating from TD Cowen Analyst | D - GuruFocus
Brokerages Set Bright Minds Biosciences Inc. (NASDAQ:DRUG) Target Price at $83.25 - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Research Coverage Started at Chardan Capital - Defense World
Chardan Capital Initiates a Buy Rating on Bright Minds Biosciences (DRUG) - The Globe and Mail
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside - Benzinga
(DRUG) On The My Stocks Page - news.stocktradersdaily.com
Chardan Capital Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy Recommendation - Nasdaq
Chardan sets Bright Minds stock Buy rating, $80 target By Investing.com - Investing.com India
Chardan sets Bright Minds stock Buy rating, $80 target - Investing.com
Piper Sandler Reaffirms Their Buy Rating on Bright Minds Biosciences (DRUG) - The Globe and Mail
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study - The Manila Times
Major Epilepsy Breakthrough? Phase 2 Trial Results for Revolutionary Seizure Drug Coming May 20 - Stock Titan
Piper Sandler sets $93 target for Bright Minds Biosciences stock - MSN
Uncover the Best-Performing Canadian Biotech Stocks of 2025 - Investing News Network
Bright Minds Biosciences Inc (DRUG) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):